Identification of a Seven-Differentially Expressed Gene-Based Recurrence-Free Survival Model for Melanoma Patients.

Melanoma is a malignant tumor that originates in melanocytes of the skin or mucous membrane, which has a high mortality rate and worse prognosis. Therefore, perspective prognosis evaluation seems more important for patients' treatment. Gene expression profiles of melanoma were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, respectively. 130 consistent differentially expressed genes (DEGs) were identified between melanoma and nevus tissues from two GEO cohorts. Prognostic genes were identified by univariate analysis, and 20 of them were regarded to be associated with the recurrence-free survival (RFS) of melanoma patients. Then, the LASSO Cox regression analysis chose seven of them to establish a seven-DEG-based RFS predicting signature. We demonstrated that this model was more powerful to predict RFS risk than other individual clinical features and was able to independently predict the RFS outcomes in different subsets of patients. We attempted to search for the underlying mechanisms by analyzing the coexpression genes of the seven candidates, and the pathway enrichment analyses indicated that immune response-related pathways might play a critical role in melanoma progression. Finally, we establish a robust seven-DEG-based RFS predicting signature, which will facilitate the personalized treatment of melanoma patients.